Table 3.
Clinical and biochemical characteristics and treatment outcomes of patients with GH excess and PP from PUMCH.
| Patient ID | Pretreatment | Posttreatment | Outcome | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GH nadir(µg/L) | IGF-1Z-score | PRL(µg/L) | ALPZ-score | MRI (largest diameter; mm) | Treatment for GH excess | IHC postivity | GH nadir(µg/L) | IGF-1Z-score | PRL(µg/L) | ALPZ-score | ||
| 1 | 35.3 | 10.2 | 204.4 | +5.25 | Macro (24) | Surgery+LAR+DA | GH,PRL | 3.1 | 0.3 | 24.4 | +1.48 | PR |
| 2 | 8.3 | 7.8 | 21.0 | +9.97 | NA | None | – | – | – | – | NA | |
| 3 | NA | 10.0 | 143.4 | +5.54 | Macro (14) | LAR + Surgery | GH,PRL | 2.52 | 2.64 | 21.1 | +4.85 | PR |
| 4 | 5.9 | 2.2 | 13.7 | +17.50 | Micro (7) | Surgery | GH | 0.1 | −0.6 | 7.8 | +16.39 | CR |
| 5 | 5.2 | 6.9 | 51.8 | +6.22 | Multiple micro | Surgery | GH | 0.748 | −0.9 | 22.1 | +5.32 | CR |
| 6 | 21.4 | 5.7 | 47.7 | +14.24 | Macro (19) | Surgery+DA | GH | 6.4 | 5.0 | 4.7 | +11.02 | PR |
| 7 | 3.0 | 2.0 | 11.19 | +21.28 | Absence | None | – | – | – | – | – | |
GH, growth hormone; IGF-1, insulin-like growth factor-1; PRL, prolactin; ALP, alkaline phosphatase; Macro, macroadenoma; Micro, microadenoma; LAR, long-acting somatostatin analogue octreotide; DA, dopamine agonist; NA, not available. The reference value for GH nadir is less than 1 µg/L. The reference value of prolactin for females is less than 30 µg/L in female patients, and 2.6~13.1 µg/L in male patients.